Other Routine +

MedX Health Launches SkinSecure(TM) to Bring Direct, Non-Invasive, Objective Biological Measurement to Skin Health Research

MedX Health Launches SkinSecure SaaS to Target CRO Market, But Liquidity Crisis and Going Concern Risks Dominate

By The Northwire Desk — AI Analysis Jun 25, 2026 · 23:52 MDX · 0.055 Medx Health Corp.

Executive Summary

MedX Health Corp. announced the commercial launch of SkinSecure™, a cloud-based SaaS platform that integrates with its proprietary SIAscope imaging devices.
The platform delivers non-invasive, quantitative mapping of collagen, melanin, and hemoglobin for clinical research workflows.
It is designed to replace expensive, invasive punch biopsies in clinical trials, offering immediate objective biomarker data across multiple sites.
Full commercial deployment is scheduled for July 2026, targeting dermatology trials, aesthetic studies, and pharmaceutical development.
The technology is intended for investigational use only and is not approved for diagnostic or routine clinical care.
The core SIAscopy technology has already been utilized by over 29 CROs and sponsors globally.

Material Impact

The launch represents a commercialization milestone for MedX's existing SIAscopy/DermSecure ecosystem, but it does not fundamentally alter the company's financial trajectory or risk profile.
The addressable market (clinical research CROs) is niche, and sales cycles in this sector are historically long and capital-intensive.
The stock has traded in a tight $0.05–$0.06 range for over a year, indicating the market has already priced in the incremental nature of this rollout.
The announcement does not address the company's severe liquidity constraints, negative working capital, or going concern status. It is a follow-up to prior development milestones and financing rounds.

MDX · Price

Company Overview

MedX Health Corp. operates in the medical device and digital health space, focusing on non-invasive skin health measurement and photobiomodulation therapies.
Core assets include the DermSecure® telemedicine platform and SIAscopy® imaging technology, which capture biological data (collagen, melanin, hemoglobin) without biopsies.
The company also operates a photobiomodulation division producing laser devices for veterinary (LumaVet) and dental (Oralase) applications.
Strategic focus is shifting toward SaaS-based clinical research tools and occupational health markets, leveraging an expanding database of ~85,000 clinically reviewed skin images.

More from Medx Health Corp.